WallStSmart

Akso Health Group ADR (AHG)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 90075% more annual revenue ($13.38B vs $14.84M). HSIC leads profitability with a 3.0% profit margin vs 0.0%. HSIC earns a higher WallStSmart Score of 52/100 (C-).

AHG

Avoid

16

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 6.0Quality: 7.5
Piotroski: 2/9Altman Z: 7.29

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+18.0%)

Margin of Safety

+18.0%

Fair Value

$1.72

Current Price

$1.34

$0.38 discount

UndervaluedFair: $1.72Overvalued
HSICUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$153.40

Current Price

$77.45

$75.95 discount

UndervaluedFair: $153.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.2910/10

Safe zone — low bankruptcy risk

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

AHG4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.9%4/10

0.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.15B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.794/10

Expensive relative to growth rate

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.153/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : AHG

The primary concerns for AHG are Revenue Growth, EPS Growth, Market Cap.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, EPS Growth, Profit Margin. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

HSIC carries more volatility with a beta of 0.82 — expect wider price swings.

HSIC is growing revenue faster at 6.3% — sustainability is the question.

AHG generates stronger free cash flow (3M), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HSIC scores higher overall (52/100 vs 16/100). AHG offers better value entry with a 18.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading innovator in the healthcare sector, focused on delivering advanced medical solutions and comprehensive patient care services. The company harnesses state-of-the-art health technologies to drive growth in areas such as telehealth and personalized medicine, supported by a strong emphasis on research and development. With a resilient business model and a dedicated team, Akso Health Group presents an attractive investment opportunity for institutional investors, poised to capitalize on the ongoing transformation within the healthcare industry.

Visit Website →

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?